MBD4: A Potential Drug Target for Various Diseases (G8930)

Target Name: MBD4

NCBI ID: G8930

MBD4

MBD4: A Potential Drug Target for Various Diseases

MBD4, also known as Methyl-CpG-binding domain protein 4, is a protein that plays a crucial role in various cellular processes. It is a non-coding RNA-binding protein that is expressed in various tissues and cells in the body. One of its main functions is to regulate gene expression by binding to specific DNA sequences, including methylated CpG dinucleotides.

MBD4 has been identified as a potential drug target and has been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to a growing interest in developing new treatments that target MBD4.

In cancer, MBD4 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. It has also been shown to play a role in the development of resistance to chemotherapy in cancer cells. Therefore, MBD4 has been identified as a potential target for cancer treatment.

MBD4 has also been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a wide range of symptoms, including cognitive decline, hallucinations, and difficulty with daily tasks.

MBD4 has been shown to be involved in the regulation of inflammation and immune response. It has been shown to play a role in the regulation of T cell responses and has been shown to contribute to the development of autoimmune disorders. Therefore, MBD4 has been identified as a potential target for the treatment of autoimmune disorders.

MBD4 has also been shown to be involved in various cellular processes that are important for cell survival and integrity. It has been shown to play a role in the regulation of DNA replication, cell division, and apoptosis. Therefore, MBD4 has been identified as a potential target for the treatment of diseases that are characterized by disruptions in cellular processes, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, MBD4 is a protein that has been shown to play a role in various cellular processes that are important for cell survival and integrity. Its potential as a drug target has led to a growing interest in developing new treatments that target MBD4. Further research is needed to fully understand the role of MBD4 in various diseases and to develop effective treatments.

Protein Name: Methyl-CpG Binding Domain 4, DNA Glycosylase

Functions: Mismatch-specific DNA N-glycosylase involved in DNA repair. Has thymine glycosylase activity and is specific for G:T mismatches within methylated and unmethylated CpG sites. Can also remove uracil or 5-fluorouracil in G:U mismatches. Has no lyase activity. Was first identified as methyl-CpG-binding protein

The "MBD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets